Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
Medicines Excitement in the Netherlands – New Health Minister announces firm action on...
The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced...
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. »
L’augmentation croissante du prix...
Pharmaceutical Pricing Hostages
Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring...
Dolutegravir Patent Licences Can Provide Access To All
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...
The Most Common Misunderstanding about Compulsory Licensing
The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to...
The Italian Exception – A personalised approach to accessing high-priced patented medicines
At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...
Access to medicines amendment of the WTO TRIPS Agreement. Hype or hope?
On 30 January 2017 the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome...
UN High-Level Panel on Access to Medicines calls for stronger public leadership in innovation...
The UN High-Level Panel on Access to Medicines published its report on 14 September. The Panel was established on 19 November 2015 by UN...
High medicines prices in Europe – do not Brexit the people
The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...